Alongside features like physicochemical properties and structural alerts, it is becoming apparent that a detailed analysis of drug-protein binding thermodynamics and kinetics can significantly improve Lead and Clinical Candidate quality.
This symposium will cover the current thinking around the integration of thermodynamic- and kinetic-based approaches into Drug Discovery, how these approaches may relate to other measures of 'Developability' and how they may be used to identify Clinical Candidates with enhanced in vivo efficacy whilst reducing potential off-target adverse events.
This symposium will cover the current thinking around the integration of thermodynamic- and kinetic-based approaches into Drug Discovery, how these approaches may relate to other measures of 'Developability' and how they may be used to identify Clinical Candidates with enhanced in vivo efficacy whilst reducing potential off-target adverse events.
